Skip to main content
Signal8

Tevogen Inc. (TVGNW)

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. Their research and development efforts span virology, oncology, and neurological conditions. The company's flagship experimental treatment, TVGN 489, is a precision T cell product designed to meet the unmet needs of individuals severely affected by acute COVID-19, as well as a specific group of patients struggling with long COVID. Tevogen Bio Holdings Inc. is headquartered in Warren, New Jersey.

Sector: Biological Products, (No Diagnostic Substances)

Tevogen Inc. logo

Tevogen Inc.

NASDAQ:TVGNWSub-class of TVGN
-2.64%$0.0847
CLOSED
AH$0.0880+3.90%vs close
Mkt Cap$5.75M
Float43.58M
O/S67.88M
VOL759K sh
$ Vol$62K
RVOL1.50×
Inst Own-
SI0.2%
EarningsNov 13 · in 4d
Dilution
Tevogen Inc. logoNASDAQ:TVGNWClosed$0.0847-2.64%
Trials1 trial as collaborator·0 active1 completed(no lead-sponsored trials found)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Phase 1
    Completed

    Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

    Collaborator · Lead: Thomas Jefferson University

    Cytotoxic T Lymphocytes

    Covid19

    Enrollment
    30
    Start
    Sep 2021
    Primary Completion
    Jul 2022
    Completion
    Jan 2023
    NCT04765449
Search ClinicalTrials.gov for “Tevogen”